For patients with chronic lymphocytic leukemia (CLL) treated previously with venetoclax and Bruton’s tyrosine kinase ...

The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer ... the disease will progress and help your doctor choose which treatment options to use. The genetic testing to find such changes ...

Alessandra Ferrajoli, MD, discusses the importance of supportive care in the management of patients with chronic lymphocytic ...

Imbruvica was studied in people with CLL or SLL who were 65 and older and did not receive any prior treatment for their leukemia. People in this study got either Imbruvica or chemotherapy.

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...

Nurix Therapeutics (NRIX) announced that the European Medicines Agency, or EMA, has granted PRIME designation for NX-5948, a highly selective ...

GEO-CM04S1 Improved Immune Response vs mRNA VaccineATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology ...

This drug is used not only in AML but also in chronic lymphocytic leukemia. In AML, the combination of venetoclax with an older drug called azacytidine has been approved for older patients. This ...

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...